NZ333845A - Long-acting Fmoc-substituted and Fm-substituted pro-drugs - Google Patents
Long-acting Fmoc-substituted and Fm-substituted pro-drugsInfo
- Publication number
- NZ333845A NZ333845A NZ333845A NZ33384597A NZ333845A NZ 333845 A NZ333845 A NZ 333845A NZ 333845 A NZ333845 A NZ 333845A NZ 33384597 A NZ33384597 A NZ 33384597A NZ 333845 A NZ333845 A NZ 333845A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fmoc
- prodrugs
- substituted
- carboxyl
- radical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-07 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
| PCT/IL1997/000265 WO1998005361A2 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ333845A true NZ333845A (en) | 2000-09-29 |
Family
ID=11069166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ333845A NZ333845A (en) | 1996-08-07 | 1997-08-05 | Long-acting Fmoc-substituted and Fm-substituted pro-drugs |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6504005B1 (enExample) |
| EP (1) | EP1019089B1 (enExample) |
| JP (1) | JP4416184B2 (enExample) |
| KR (1) | KR20000029806A (enExample) |
| CN (1) | CN1227501A (enExample) |
| AT (1) | ATE308998T1 (enExample) |
| AU (1) | AU725468B2 (enExample) |
| BR (1) | BR9711045A (enExample) |
| CA (1) | CA2261835C (enExample) |
| CZ (1) | CZ36999A3 (enExample) |
| DE (1) | DE69734607T2 (enExample) |
| DK (1) | DK1019089T3 (enExample) |
| ES (1) | ES2252787T3 (enExample) |
| HU (1) | HUP0000809A2 (enExample) |
| IL (3) | IL119029A0 (enExample) |
| NO (1) | NO990518L (enExample) |
| NZ (1) | NZ333845A (enExample) |
| WO (1) | WO1998005361A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139400A0 (en) * | 2000-11-01 | 2001-11-25 | Yeda Res & Dev | Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| EP2186824A3 (en) * | 2000-12-13 | 2010-09-22 | Eli Lilly & Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| BRPI0213425B8 (pt) | 2001-10-19 | 2021-05-25 | Idexx Lab Inc | composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| JP4033382B2 (ja) * | 2002-04-08 | 2008-01-16 | 久光製薬株式会社 | インスリン投与装置 |
| DE602004030212D1 (de) * | 2003-01-16 | 2011-01-05 | Caprotec Bioanalytics Gmbh | Verfahren zur identifizierung von auf arzneimittel nicht-zielgerichteten proteinen |
| CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| ATE347358T1 (de) * | 2003-04-17 | 2006-12-15 | Jallal Messadek | Schwimmende orale formulierungen mit kontrollierter freisetzung von betain |
| EP2107069B1 (en) | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| CN101180073A (zh) * | 2005-04-27 | 2008-05-14 | 贾拉尔·梅萨德克 | 胰岛素组合 |
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
| WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
| EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| WO2010048184A2 (en) * | 2008-10-21 | 2010-04-29 | Baxter International Inc. | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| KR20110085985A (ko) * | 2008-10-30 | 2011-07-27 | 노보 노르디스크 에이/에스 | 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료 |
| CN102413843A (zh) | 2009-03-05 | 2012-04-11 | 阿森迪斯药物股份有限公司 | 干扰素α载体前药 |
| WO2011013128A2 (en) | 2009-07-31 | 2011-02-03 | Yeda Research And Development Co. Ltd. | Vectors for delivery of neurotherapeutics to the central nervous system |
| ES2584381T3 (es) * | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| EP2490378B1 (en) | 2011-02-18 | 2014-07-09 | NTT DoCoMo, Inc. | Apparatus and method for determining a control unit using feasibility requests and feasibility responses |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| EP2714070B1 (en) | 2011-06-02 | 2024-03-20 | OPKO Biologics Ltd. | Long-acting glp-1/glucagon receptor agonists |
| CA2870313A1 (en) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Insulin formulations |
| PE20150181A1 (es) | 2012-06-04 | 2015-02-28 | Opko Biolog Ltd | Variantes de oxm pegilada |
| EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
| JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| ES2886837T3 (es) | 2016-12-16 | 2021-12-21 | Novo Nordisk As | Composiciones farmacéuticas que contienen insulina |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| US20200254065A1 (en) | 2019-02-11 | 2020-08-13 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
| CN114630818A (zh) | 2019-09-30 | 2022-06-14 | 北京轩义医药科技有限公司 | 蛋白-大分子偶联物及其使用方法 |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| CN117551008B (zh) * | 2023-11-10 | 2025-10-17 | 沈阳药科大学 | 一种去铁胺偶联物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU906341D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US6313094B1 (en) * | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| JPH0687887A (ja) * | 1992-08-19 | 1994-03-29 | Upjohn Co:The | ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤 |
| US5631222A (en) | 1993-06-25 | 1997-05-20 | Kyowa Hakko Kogyo Co., Ltd. | Endothelin-antagonizing peptide |
| US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| DE4437604A1 (de) * | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| JPH10511340A (ja) | 1995-02-09 | 1998-11-04 | ブリガム アンド ウィメンズ ホスピタル | ゲル生成ポリペプチド誘導体 |
| AU5377296A (en) * | 1995-03-30 | 1996-10-16 | Southpac Trust International, Inc. | Self-erecting container which is collapsible to be substanti ally flat |
| US5688992A (en) * | 1995-03-31 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof |
| US5846934A (en) * | 1996-02-20 | 1998-12-08 | American Cyanamid Company | Pure somatostatin antagonist and methods of use thereof |
| US6057297A (en) * | 1996-08-06 | 2000-05-02 | Polifarma S.P.A. | Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof |
-
1996
- 1996-08-07 IL IL11902996A patent/IL119029A0/xx unknown
-
1997
- 1997-08-05 EP EP97933828A patent/EP1019089B1/en not_active Expired - Lifetime
- 1997-08-05 WO PCT/IL1997/000265 patent/WO1998005361A2/en not_active Ceased
- 1997-08-05 CN CN97197122A patent/CN1227501A/zh active Pending
- 1997-08-05 BR BR9711045A patent/BR9711045A/pt not_active IP Right Cessation
- 1997-08-05 IL IL12827497A patent/IL128274A0/xx active IP Right Grant
- 1997-08-05 NZ NZ333845A patent/NZ333845A/xx unknown
- 1997-08-05 DE DE69734607T patent/DE69734607T2/de not_active Expired - Lifetime
- 1997-08-05 KR KR1019997000941A patent/KR20000029806A/ko not_active Withdrawn
- 1997-08-05 AT AT97933828T patent/ATE308998T1/de active
- 1997-08-05 JP JP50777098A patent/JP4416184B2/ja not_active Expired - Lifetime
- 1997-08-05 HU HU0000809A patent/HUP0000809A2/hu unknown
- 1997-08-05 CA CA002261835A patent/CA2261835C/en not_active Expired - Lifetime
- 1997-08-05 ES ES97933828T patent/ES2252787T3/es not_active Expired - Lifetime
- 1997-08-05 CZ CZ99369A patent/CZ36999A3/cs unknown
- 1997-08-05 AU AU37060/97A patent/AU725468B2/en not_active Ceased
- 1997-08-05 US US09/242,026 patent/US6504005B1/en not_active Expired - Lifetime
- 1997-08-05 DK DK97933828T patent/DK1019089T3/da active
-
1999
- 1999-01-28 IL IL128274A patent/IL128274A/en not_active IP Right Cessation
- 1999-02-04 NO NO990518A patent/NO990518L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2252787T3 (es) | 2006-05-16 |
| WO1998005361A2 (en) | 1998-02-12 |
| HUP0000809A2 (hu) | 2000-11-28 |
| EP1019089A2 (en) | 2000-07-19 |
| AU3706097A (en) | 1998-02-25 |
| IL128274A0 (en) | 1999-11-30 |
| DK1019089T3 (da) | 2006-03-13 |
| NO990518L (no) | 1999-04-06 |
| NO990518D0 (no) | 1999-02-04 |
| JP4416184B2 (ja) | 2010-02-17 |
| US6504005B1 (en) | 2003-01-07 |
| IL119029A0 (en) | 1996-11-14 |
| AU725468B2 (en) | 2000-10-12 |
| BR9711045A (pt) | 1999-08-17 |
| CA2261835C (en) | 2008-07-29 |
| WO1998005361A3 (en) | 1998-06-18 |
| DE69734607D1 (de) | 2005-12-15 |
| DE69734607T2 (de) | 2006-08-03 |
| IL128274A (en) | 2006-08-01 |
| CN1227501A (zh) | 1999-09-01 |
| KR20000029806A (ko) | 2000-05-25 |
| JP2000515542A (ja) | 2000-11-21 |
| CZ36999A3 (cs) | 1999-07-14 |
| ATE308998T1 (de) | 2005-11-15 |
| EP1019089B1 (en) | 2005-11-09 |
| CA2261835A1 (en) | 1998-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998005361A3 (en) | Long-acting drugs and pharmaceutical compositions comprising them | |
| MD420C2 (ro) | Derivaţi ai acidului acrilic | |
| FI93450B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 10-(1-hydroksietyyli)-11-okso-1-atsatrisyklo/7.2.0.03,8/undek-2-eeni-2-karboksyylihappojohdannaisten valmistamiseksi | |
| ES2127948T3 (es) | Oligonucleotidos modificados en la posicion 2'-amido y 2'-peptido. | |
| NZ334061A (en) | 2,6,9-trisubstituted purine compounds useful as inhibitors of cyclin dependent kinase 2 | |
| MY100574A (en) | 5-substituted-2-cyclopropyl-6, 8-difluoroquinoline derivatives and processes for preparation thereof | |
| NO20020623L (no) | Farmasöytiske forbindelser | |
| ATE223424T1 (de) | Quinazolinon-verbindungen | |
| MX9800577A (es) | Derivados de 4,5-diaril oxazol. | |
| OA09785A (en) | Antiviral or antibacterial compound and method of use | |
| AU1227795A (en) | Cosmetic or pharmaceutical compositions consisting of liposomes | |
| EP1304329A3 (en) | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | |
| WO2001026629A3 (en) | Neutral-cationic lipid for nucleic acid and drug delivery | |
| MX9804226A (es) | Derivados novedosos de 2,3,5-trimetil-4-hidroxianilida, su preparacion y su aplicacion de terapeutica. | |
| DE69600956D1 (de) | N,N'-Di(aralkyl)-N,N'-di(2-azaaralkyl)alkylendiamin-Derivate und ihre Verwendung in pharmazeutischen und kosmetischen Zusammensetzungen | |
| HUT55032A (en) | Process for producing 19-norsteroids comprising carbon chain substituted in 11beta position by amide or carbamagte group, as well as pharmaceutical compositions comprising such compounds as active ingredient | |
| TW287103B (enExample) | ||
| EP0774462A4 (en) | HETEROCYCLIC COMPOUND | |
| DE69501359D1 (de) | Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina | |
| HU9201575D0 (en) | Pyrimidone derivatives and their analogues | |
| MY132057A (en) | Quinoxalinones, a process for their preparation and their use | |
| HU9201033D0 (en) | Tiazolidinone- and oxazolidinone derivatives, process for their production, and for the production of medical preparations containing them as active agents | |
| GB9904275D0 (en) | Anti-cancer compounds | |
| HUP9900968A2 (hu) | Herbicid hatású szubsztituált-3-aril-pirazol vegyületek, ezeket tartalmazó készítmények, eljárás alkalmazásukra valamint eljárás a vegyületek előállítására | |
| TR199801196T2 (xx) | Biyolojik aktif benzotiyazolon etanaminler. |